TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search results
The US National Institutes of Health said on Saturday it has halted a clinical trial to evaluate the safety and effectiveness of the malaria drug hydroxychloroquine for the treatment of hospitalized COVID-19 patients.
Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against COVID-19 after struggling to find participants, it said on Friday, as data emerged from other studies raising doubts about its efficacy.
The World Health Organization said on Wednesday that testing of the malaria drug hydroxychloroquine in its large multi-country trial of treatments for COVID-19 patients had been halted after new data and studies showed no benefit.
The US Food and Drug Administration on Monday revoked its emergency use authorization for hydroxychloroquine to treat COVID-19, but quickly came under fire from President Donald Trump, who said only US agencies have failed to grasp its benefit in fighting the coronavirus.
The United States on Monday withdrew emergency use authorizations for two antimalarial drugs favored by President Donald Trump to treat the new coronavirus, effectively shutting the door on the politically charged treatments.
Hydroxychloroquine, a decades-old malaria and rheumatoid arthritis drug, has been touted as a possible treatment for the new coronavirus by high profile figures, including US President Donald Trump, and has been included in several randomized clinical trials.
Dozens of scientists have raised concerns over a large-scale study of hydroxychloroquine and chloroquine published in the Lancet that led to the World Health Organization suspending clinical trials of the anti-viral drugs as a potential treatment for COVID-19.
Novartis has won the go-ahead from the US Food and Drug Administration to conduct a randomized trial of malaria drug hydroxychloroquine against COVID-19 disease, the Swiss drugmaker said on Monday, to see if it helps patients.
